一种基于金属聚的抗抑郁药,用于缓解结肠炎相关的精神障碍
Zihao Wang1, Zi-Xi Wang1, Ke-Fei Xu1
1State Key Laboratory of Digital Medical Engineering, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 211189, P. R. China.
一种新的金属多抗抑郁药,CSMTC,通过向微生物群-肠-大脑轴,有效地治疗大肠炎小鼠的抑郁症. 这种纳米药物恢复了肠道健康,减少了神经炎症,并在炎症性肠病模型中改善了心理健康.
科学领域:
- 纳米医学是一种纳米医学.
- 神经科学是一个神经科学.
- 胃肠病学 胃肠病学
背景情况:
- 炎症性肠道疾病 (IBD) 与抑郁症和焦虑症等心理社会问题有关.
- 目前的抗抑郁药通常对IBD相关的心理健康问题是无效的,原因是肠-大脑轴功能障碍.
研究的目的:
- 开发和评估一种基于金属多的抗抑郁药 (CSMTC) 用于治疗实验性结肠炎中的精神障碍.
- 通过微生物群-肠-大脑轴研究CSMTC的作用机制.
主要方法:
- 含有抗氧化酶和酸-离子网络的CSMTC被口服给硫酸诱导大肠炎的小鼠.
- 评估了对结肠氧化还原平衡,肠道屏障,肠道微生物群,血脑屏障完整性和全身免疫力的影响.
- 评估了行为变化,神经炎症,神经可塑性,以及海马中神经递质恒温.
主要成果:
- CSMTC恢复了结肠的氧化还原平衡,加强了肠道屏障,调节了肠道微生物群,并保持了血脑屏障的完整性.
- 在大肠炎小鼠中,CSMTC显著缓解了类似抑郁症的行为.
- 该机制涉及减少神经炎症,增强海马体的可塑性,并通过微生物群-肠-大脑轴恢复神经递质平衡.
结论:
- 通过调节微生物群-肠-大脑轴,CSMTC证明了对IBD相关精神障碍的治疗潜力.
- 这种金属多纳米药物为治疗与炎症相关的并发症和心理健康问题提供了有前途的策略.
更多相关视频
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
07:58Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
Published on: February 24, 2023
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Antidepressant Drugs: MAOIs and Other Agents
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
